Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ABL2 | P42684 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938505 | 0.82 | DYRK1A (0.54) | MAP4K4MGAT2DYRK1ACLK4TDO2 | |
| SCHEMBL5440563 | 0.80 | IGF1R (0.53) | — | |
| SCHEMBL27290306 | 0.78 | CLK4 (0.53) | MAP4K4DYRK1ACLK4ADORA2ABRD4 | |
| SCHEMBL5442223 | 0.77 | PIK3CD (0.52) | MAP4K4DYRK1ACLK4ADORA1FYN | |
| SCHEMBL625052 | 0.77 | FYN (0.60) | MAP4K4DYRK1ACLK4TDO2ADORA2A | |
| SCHEMBL16549165 | 0.76 | MAP4K4 (0.53) | MAP4K4MGAT2DYRK1ACLK4TDO2 | |
| SCHEMBL5444085 | 0.75 | JAK2 (0.48) | TDO2FYNBRD4 | |
| SCHEMBL13241129 | 0.74 | BRD4 (0.51) | MGAT2DYRK1ACLK4TDO2BRD4 | |
| SCHEMBL5286981 | 0.74 | BRD4 (0.55) | DYRK1ACLK4ADORA2AADORA1BRD4 | |
| SCHEMBL14115592 | 0.74 | CLK1 (0.54) | DYRK1ACLK4TDO2FYNKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007511570-A | — | — | 2007-05-10 | — | — | JP | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | claimed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | claimed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1689718-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 ACTIVITY | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049577-A1 | 1-AMINO-ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INAPPROPRIATE ALK5 | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072901-A1 | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | ALK, NPR3, CBR3 | MAP4K4 2454/4885MGAT2 2142/4885DYRK1A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.